Industry Developments
Greece
BMI View: Greece's failure to aggressively cut public pharmaceutical expenditure in 2011 means these savings will have to be achieved in 2012, placing additional pressure on the already...
2012-02-06Ukraine
BMI View: Three main factors govern our outlook for Ukraine's pharmaceutical market in 2012 and 2013: the worsening economic growth prospects, the high potential for devaluation of...
2012-02-01Switzerland
BMI View: We believe the long-awaited formation of a joint venture (JV) between Actavis and Bioton in the field of insulin production and commercialisation is highly favourable for...
2012-02-01Romania
BMI View: While there has been no immediate impact on Romania's health system following the withdrawal of the draft healthcare reform bill, the development is bad news for private healthcare...
2012-01-16Turkey
BMI View: While the Turkish pharmaceutical industry has achieved some concessions following additional price cuts and public discounts announced in November 2011, the impact of the...
2012-01-06Turkey
BMI View: Following the BMI Country Risk team's downgrade to Turkey's 2012 macroeconomic projections, BMI's Pharmaceutical and Healthcare team have moderately revised the growth expectations...
2011-12-15Bulgaria
BMI View: Sopharma's successful transition from a domestically focused drugmaker to a substantial exporter of pharmaceuticals to Eastern and South Eastern Europe underlines its potential...
2011-12-13Russia
BMI View: We believe Russia's latest healthcare reform law will act as a further modernising force and, due to late-stage amendments, is broadly positive for the pharmaceutical industry....
2011-12-12
